Evidence map›Paper›PMID 29372535›Full record

ArticleEndocrine pathology2018

PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.

Matthew W Rosenbaum, Benjamin J Gigliotti, Sara I Pai, Sareh Parangi, Heather Wachtel, Mari Mino-Kenudson, Viswanath Gunda, William C Faquin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
2.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Matthew W RosenbaumDepartment of Pathology, Massachusetts General Hospital, Warren 219, 55 Fruit Street, Boston, MA, 02114, USA. mrosenbaum2@partners.org.ORCID http://orcid.org/0000-0001-9897-5137
Benjamin J GigliottiDepartment of Surgery, Massachusetts General Hospital, 15 Parkman Street, Boston, MA, 02114, USA.
Sara I PaiDepartment of Surgery, Massachusetts General Hospital, 15 Parkman Street, Boston, MA, 02114, USA.
Sareh ParangiDepartment of Surgery, Massachusetts General Hospital, 15 Parkman Street, Boston, MA, 02114, USA.
Heather WachtelDepartment of Surgery, Massachusetts General Hospital, 15 Parkman Street, Boston, MA, 02114, USA.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital, Warren 219, 55 Fruit Street, Boston, MA, 02114, USA.
Viswanath GundaDepartment of Surgery, Massachusetts General Hospital, 15 Parkman Street, Boston, MA, 02114, USA.
William C FaquinDepartment of Pathology, Massachusetts General Hospital, Warren 219, 55 Fruit Street, Boston, MA, 02114, USA. wfaquin@partners.org.
Massachusetts General Hospital · US

Funding

TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETEST32DK007028 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Karen K Miller · 1986 to 2026
$18.5M
The Role of BRAF Mutation in Thyroid Cancer InvasionR01CA149738 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PARANGI, SAREH · 2011 to 2015
$1.6M
Immune Checkpoints and HPV-associated Head and Neck CancersR01DE025340 · NIDCR · MASSACHUSETTS GENERAL HOSPITAL · PI PAI, SARA ISABEL · 2015 to 2017
$1.3M
National Institutes of Health 1R01CA149738-01National Institutes of Health 5T32DK00702842National Institutes of Health R01DE025340NCI NIH HHS R01 CA149738NIDCR NIH HHS R01 DE025340NIDDK NIH HHS T32 DK007028Stand Up To Cancer Stand Up To Cancer-American Cancer Society Dream Team Translation Research Grant
6 · The paper itself

Abstract

Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of thyroid cancer that currently has limited effective treatment options. Immune checkpoint inhibitors (ICIs) have shown to be an effective treatment for a variety of carcinomas. In this study, we explore whether immune checkpoint pathways, such as programmed cell death ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO1), are activated in a cohort of patients with PDTC to determine whether ICIs may be an effective therapy for these patients. PDTC from 28 patients were stained for IDO1, PD-L1, and CD8 using immunohistochemistry. Staining was scored using an H-score, and PD-L1 and IDO1 expression was correlated with clinicopathologic characteristics. Positivity for PD-L1 and IDO1 was set at an H-score cutoff of five. Twenty-five percent (n = 7/28) of the PDTC were positive for PD-L1 expression. Twenty-nine percent (n = 2/7) of the PD-L1 positive PDTCs also co-expressed IDO1. The expression of PD-L1 in PDTC was significantly associated with tumor size and multifocality, with a non-significant trend towards associations with older age, extrathyroidal extension, presence of metastasis, higher stage, increased number of CD8+ T cells, and decreased disease-free and overall survival. PD-L1 expression occurs in a subset of PDTC, and is associated with a subset of clinical features of aggressive thyroid disease. Given the limited effective treatments for this patient population, consideration for ICIs as monotherapy or in combination with an IDO1 inhibitor should be explored as a novel treatment modality for patients with PDTC.

Indexed as

AdenocarcinomaAdolescentAdultAgedAged, 80 and overB7-H1 AntigenBiomarkers, TumorDisease-Free SurvivalFemaleHumansIndoleamine-Pyrrole 2,3,-DioxygenaseKaplan-Meier EstimateMaleMiddle AgedThyroid NeoplasmsYoung AdultB7-H1 AntigenBiomarkers, TumorCD274 protein, humanIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseIDO1Immune checkpointImmuno-oncologyIndoleamine 2,3-dioxygenase 1PD1PD-L1Poorly differentiated thyroid carcinomaProgrammed cell death ligand 1

Identifiers

PMID29372535
PMCPMC6500591
OpenAlexW2789698351

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.